Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Cytokinetics Inc’s stock clocked out at $54.40, up 0.13% from its previous closing price of $54.33. In other words, the price has increased by $0.13 from its previous closing price. On the day, 0.85 million shares were traded. CYTK stock price reached its highest trading level at $56.3002 during the session, while it also had its lowest trading level at $54.22.
Ratios:
To gain a deeper understanding of CYTK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 7.28 whereas as Long-Term Debt/Eq ratio is at 7.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 13, 2024, Downgraded its rating to Neutral and sets its target price to $60 from $85 previously.
On January 24, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $61 to $92.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 05, 2024, whereas the target price for the stock was revised from $60 to $90.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 09 ’24 when ROBERT BLUM bought 5,000 shares for $55.61 per share.
Malik Fady Ibraham sold 7,300 shares of CYTK for $380,297 on Oct 01 ’24. The EVP Research & Development now owns 118,920 shares after completing the transaction at $52.10 per share. On Oct 01 ’24, another insider, FADY MALIK, who serves as the Officer of the company, bought 7,300 shares for $52.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6400704000 and an Enterprise Value of 6134082048. For the stock, the TTM Price-to-Sale (P/S) ratio is 2044.95 while its Price-to-Book (P/B) ratio in mrq is 58.90. Its current Enterprise Value per Revenue stands at 1957.269 whereas that against EBITDA is -12.438.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $30.10. The 50-Day Moving Average of the stock is -1.40%, while the 200-Day Moving Average is calculated to be -15.07%.
Shares Statistics:
It appears that CYTK traded 1.26M shares on average per day over the past three months and 996010 shares per day over the past ten days. A total of 117.66M shares are outstanding, with a floating share count of 113.74M. Insiders hold about 3.33% of the company’s shares, while institutions hold 113.82% stake in the company. Shares short for CYTK as of 1726185600 were 17844332 with a Short Ratio of 14.19, compared to 1723680000 on 18634439. Therefore, it implies a Short% of Shares Outstanding of 17844332 and a Short% of Float of 23.169999999999998.
